Expression profiles for colon cancer and methods of use

• US 20040146921A1
• Filed: 01/23/2004
• Published: 07/29/2004
• Est. Priority Date: 01/24/2003
• Status: Abandoned Application

• Current Assignee: Bayer Pharmaceuticals Corporation (Bayer AG)
• Original Assignee: Bayer Pharmaceuticals Corporation (Bayer AG)
• Inventors: Taylor, Ian, Bigwood, Douglas, Eveleigh, Deepa
• Application Number:
  US10/764,425
• Publication Number:
  US 20040146921A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds

Abstract

The present invention relates to gene expression profiles for colon cancer, microarrays comprising nucleic acid sequences representing gene expression profiles, and methods of using expression profiles and microarrays. The invention also provides methods and compositions for diagnostic assays for detecting cancer and therapeutic methods and compositions for treating cancer. The invention also provides methods for designing, identifying, and optimizing therapeutics for cancer.

Claims

1. A method for providing a patient diagnosis for colon cancer, comprising the steps of:

(a) determining the level of expression of one or more genes or gene products in a first biological sample taken from the patient;

(b) determining the level of expression of one or more genes or gene products in at least a second biological sample taken from a normal patient sample; and

(c) comparing the level of expression of one or more genes or gene products in the first biological sample with the level of expression of one or more genes or gene products in the second biological sample;

wherein a change in the level of expression of one or more genes or gene products in the first biological sample compared to the level of expression of one or more genes or gene products in the second biological sample is a diagnostic of the disease.

2. The method of claim 1, wherein one or more genes are selected from the group consisting of SEQ ID NOs:

1-96.

3. The method of claim 1, wherein one or more gene products are polypeptides selected from the group consisting of SEQ ID NOs:

97-191.

4. A method for distinguishing between normal and disease tissues, comprising the steps of:

(a) determining the level of expression of one or more genes or gene products in a first biological sample of a disease tissue;

(b) determining the level of expression of one or more genes or gene products in at least a second biological sample taken from normal tissue; and

(c) comparing the level of expression of one or more genes or gene products in the first biological sample with the level of expression of one or more genes or gene products in the second biological sample;

wherein a change in the level of expression of one or more genes or gene products in the first biological sample compared to the level of expression of one or more genes or gene products in the second biological sample is indicative of a disease state.

5. The method of claim 4, wherein one or more genes are selected from the group consisting of SEQ ID NOs:

1-96.

6. The method of claim 4, wherein one or more gene products are polypeptides selected from the group consisting of SEQ ID NOs:

97-191.

7. A method to monitor the response of a patient being treated for colon cancer by administering a anti-cancer agent, comprising the steps of:

(a) determining the level of expression of one or more genes or gene products in a first biological sample taken from the patient prior to treatment with the anti-cancer agent;

(b) determining the level of expression of one or more genes or gene products in at least a second biological sample taken from the patient subsequent to the treatment with the anti-cancer agent; and

(c) comparing the level of expression of one or more one genes(s) or gene products in the second biological sample with the level of expression of one or more one genes(s) or gene products in the first biological sample;

wherein a change in the level of expression of one or more genes or gene products in the second biological sample compared to the level of expression of one or more genes or gene products in the first biological sample indicates the efficacy of the treatment with the anti-cancer agent.

8. The method of claim 7, wherein one or more genes are selected from the group consisting of SEQ ID NOs:

1-96.

9. The method of claim 7, wherein one or more gene products are polypeptides selected from the group consisting of SEQ ID NOs:

97-191.

10. A method for identifying a compound useful for the treatment of colon cancer comprising the steps of:

(a) analyzing the level of expression of one or more genes and/or gene products in a cell or tissue sample prior to treatment with the compound;

(b) analyzing the level of expression of one or more genes and/or gene products in a cell or tissue sample subsequent to treatment with the compound;

wherein a variation in the expression level of the gene and/or gene product is indicative of drug efficacy.

11. The method of claim 10, wherein one or more genes are selected from the group consisting of SEQ ID NOs:

1-96.

12. The method of claim 10, wherein one or more gene products are polypeptides selected from the group consisting of SEQ ID NOs:

97-191.

13. An array for distinguishing between normal and disease tissues, comprising two or more probes corresponding to two or more genes selected from the group consisting of SEQ ID NOs:

1-96.

14. An array for distinguishing between normal and disease tissues, comprising two or more polypeptides selected from the group consisting of SEQ ID NOs:

97-191.